Companion Diagnostic Stocks List Ranked for 2024 |

Symbol	Grade	Name	% Change
MACK	C	Merrimack Pharmaceuticals, Inc.	0.07
QGEN	D	Qiagen N.V.	-1.04
BDSX	D	Biodesix, Inc.	0.00
MYGN	F	Myriad Genetics, Inc.	-3.54
VSTM	F	Verastem, Inc.	-0.64

Related Industries: Biotechnology Diagnostics & Research

Symbol	Grade	Name	Weight
GNOM	F	Global X Genomics & Biotechnology ETF	6.75
PBE	D	PowerShares Dynamic Biotech & Genome	5.0
EKG	D	First Trust Nasdaq Lux Digital Health Solutions ETF	4.56
WDNA	D	WisdomTree BioRevolution Fund	2.16
BBH	D	Market Vectors Biotech ETF	1.92

Compare ETFs

Compare GNOM to PBE Compare PBE to BBH Compare PBE to EKG

Date	Stock	Title
Apr 24	QGEN	QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
Apr 24	MYGN	Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
Apr 24	QGEN	Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics
Apr 24	BDSX	Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024

Companion Diagnostic: Companion diagnostics are tests used to identify which patients are most likely to benefit from a particular therapy. They are used to identify the presence or absence of a biomarker that is associated with a particular disease or condition, and to determine the best course of treatment for a patient. Companion diagnostics are used to help physicians make more informed decisions about which treatments are most likely to be effective for a particular patient.